VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 08h00 HE
|
VYNE Therapeutics Inc.
Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarterPhase 2b trial expected to enroll approximately 160 subjects with either active or stable...
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
06 mai 2024 08h00 HE
|
VYNE Therapeutics Inc.
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic...
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
01 mai 2024 08h00 HE
|
VYNE Therapeutics Inc.
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
19 mars 2024 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
29 févr. 2024 08h00 HE
|
VYNE Therapeutics Inc.
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional...
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
27 févr. 2024 08h00 HE
|
VYNE Therapeutics Inc.
Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq:...
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
21 févr. 2024 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative,...
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
10 janv. 2024 08h00 HE
|
VYNE Therapeutics Inc.
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
03 janv. 2024 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
13 nov. 2023 07h45 HE
|
VYNE Therapeutics Inc.
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for...